Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
General Rheumatology
•
Infectious Disease
•
Immunosuppression
•
MRSA
•
Primary Care
What is your approach to a patient on immunosuppressants with an outpatient cutaneous MRSA infection or to a MRSA carrier?
Related Questions
In a patient with negative Hep B surface Ag, Hep B surface antibody+, and Hep B core antibody+ serologies, do you initiate antiviral prophylaxis (e.g. entecavir) prior to starting rituximab?
Can inflammatory arthritis develop in patients with a history of chronic hepatitis B?
In light of recent measles outbreaks, have you adjusted your vaccination counseling or preventive strategies for adult immunocompromised patients?
Is it better to give dose 2 of the mRNA 2024-2025 Covid-19 vaccine at month 2 or month 6 after dose 1 in moderately immunocompromised patients?
Would you have concerns with continuing denosumab for much longer than the available ten year clinical safety trial data for an individual with renal insufficiency with persistent osteoporosis/history of compression fractures?
Do you generally utilize calcium channel blockers on an as needed basis for patients with Raynaud's phenomenon?
How long do you recommend that a patient wear a mask when resuming biologic infusions following a recent upper respiratory infection?
How do you approach an asymptomatic patient with evidence of intense radiotracer activity at the left sternoclavicular joint on bone scan with a history of SAPHO syndrome on Humira?
Do you pursue coronary artery calcium scoring in patients with metabolic risk factors and autoimmune disease in order to guide decisions regarding GLP-1 medications?
How do you approach treatment intensification in patients with RA and low disease activity but not in remission, considering the potential risks of increased immunosuppression?
